Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521056

SCHEMBL1521056

SCHEMBL1521056

Cc1nc2ccccc2c(=O)n1O

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.64
▸ LMNA P02545 2/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ TSHR P16473 1/20 0.56
▸ HSD17B10 Q99714 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ HTT P42858 2/20 0.54
▸ POLB P06746 2/20 0.54
▸ ATM Q13315 1/20 0.54
▸ GAA P10253 1/20 0.53
▸ ALOX15 P16050 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1101889 0.79 KDM4E (0.66) KDM4ELMNACYP1A2ALDH1A1L3MBTL1
SCHEMBL27639917 0.78 KDM4E (0.64) KDM4ELMNACYP1A2ALDH1A1L3MBTL1
SCHEMBL28019873 0.78 KDM4E (0.64) KDM4ELMNACYP1A2ALDH1A1L3MBTL1
SCHEMBL1428216 0.78 KDM4E (1.00) KDM4ELMNACYP1A2ALDH1A1L3MBTL1
SCHEMBL30883267 0.78 KDM4E (1.00) KDM4ELMNACYP1A2ALDH1A1L3MBTL1
SCHEMBL7608138 0.78 KDM4E (0.64) KDM4ELMNAALDH1A1MAPK1MEN1
SCHEMBL22021637 0.78 KDM4E (0.64) KDM4ELMNACYP1A2ALDH1A1L3MBTL1
SCHEMBL10887612 0.77 SMN1; SMN2 (0.58) KDM4ELMNACYP1A2ALDH1A1L3MBTL1
SCHEMBL11014372 0.77 LMNA (0.55) KDM4ELMNAALDH1A1L3MBTL1TSHR
SCHEMBL1102251 0.76 KDM4E (0.62) KDM4ELMNACYP1A2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220401432-A1 THERAPEUTIC METHODS, COMBINATIONS AND KITS REGENTS OF THE UNIVERSITY OF MINNESOTA 2022-12-22 — — US disclosed
WO-2022033548-A1 IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF 上海科技大学 2022-02-17 — — WO disclosed
CN-101784522-B Proton acceptor iminium/carbocationic coupling agents LUXEMBOURG BIOTECHNOLOGIES LTD 2014-05-28 — — CN disclosed
US-20130289083-A1 IDO Inhibitors NEWLINK GENETICS CORPORATION 2013-10-31 — — US disclosed
US-20130289083-A1 IDO Inhibitors NEWLINK GENETICS CORPORATION 2013-10-31 — — US disclosed
US-8524898-B2 Proton acceptor iminium/carbocation-type coupling agents LUXEMBOURG BIO TECHNOLOGIES LTD. (IL) 2013-09-03 — — US disclosed
US-8524898-B2 Proton acceptor iminium/carbocation-type coupling agents LUXEMBOURG BIO TECHNOLOGIES LTD. (IL) 2013-09-03 — — US disclosed
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 — — US disclosed
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 — — US disclosed
US-20110053941-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-03-03 — — US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 — — US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 — — US disclosed
US-20100004439-A1 Heterocyclic Compound FUJIFLM CORPORATION (JP) 2010-01-07 — — US disclosed
US-20100004439-A1 Heterocyclic Compound FUJIFLM CORPORATION (JP) 2010-01-07 — — US disclosed
WO-2009138985-A2 COUPLING AGENTS FOR THE SYNTHESIS OF POLYPEPTIDES AND POLYNUCLEOTIDES LUXEMBOURG BIO TECHNOLOGIES LTD. (IL) 2009-11-19 — — WO disclosed
US-20090239982-A1 Ultraviolet Absorbent and Heterocyclic Compound FUJIFILM CORPORATION (JP) 2009-09-24 — — US disclosed
WO-2008139481-A2 PROTON ACCEPTOR IMINIUM/CARBOCATION-TYPE COUPLING AGENTS LUXEMBOURG BIO TECHNOLOGIES LTD. (IL) 2008-11-20 — — WO disclosed
WO-2008139481-A2 PROTON ACCEPTOR IMINIUM/CARBOCATION-TYPE COUPLING AGENTS LUXEMBOURG BIO TECHNOLOGIES LTD. (IL) 2008-11-20 — — WO disclosed
WO-2007147217-A1 METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR PRANA BIOTECHNOLOGY LIMITED (AU) 2007-12-27 — — WO disclosed
US-4052373-A O-AMINOESTER FUJI PHOTO FILM CO., LTD. (JA) 1977-10-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME MGMT, DHFR, IDH2 KDM4E 2823/4885LMNA 2250/4885CYP1A2 1840/4885
US-20220401432-A1 THERAPEUTIC METHODS, COMBINATIONS AND KITS MMP8, TLR7, GOT2 KDM4E 4602/4885LMNA 2213/4885CYP1A2 3255/4885
US-20090239982-A1 Ultraviolet Absorbent and Heterocyclic Compound CYP2A6, CYP2B6, XPO6 KDM4E 2273/4885LMNA 920/4885CYP1A2 38/4885
US-20110053941-A1 IDO Inhibitors IDO1, IDO2, INMT KDM4E 288/4885LMNA 4872/4885CYP1A2 410/4885
US-20130289083-A1 IDO Inhibitors IDO1, IDO2, INMT KDM4E 299/4885LMNA 4882/4885CYP1A2 450/4885
US-20100004439-A1 Heterocyclic Compound PTGER1, CYP1A1, ALOX12 KDM4E 2305/4885LMNA 1485/4885CYP1A2 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.